CD8A and cancer: Ongoing clinical trials that combine antiangiogenic agents and immunotherapies like ICB or those targeting and modulating innate immune cells as well as strategies to directly enhance infiltration and activation of CD8 T-cells validate the concept of enhancing an immunostimulating environment in cancer.